Update on molecular findings, management and outcome in low-grade gliomas

Nature Reviews Neurology

Volumn 6, Issue 12, 2010, Pages 695-701

  Bourne, T David ^a   Schiff, David ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE;

AMINO ACID SUBSTITUTION; ASTROCYTOMA; CARCINOGENESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 7; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL TRIAL; CPG ISLAND; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA METHYLATION; GLIOMA; HUMAN; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; ONCOGENE; OVERALL SURVIVAL; PHARMACOGENETICS; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; GENETIC MARKERS; GLIOMA; HUMANS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 78649906555     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.159     Document Type: Review

References (96)

1. Porter, K. R., Mccarthy, B. J., Freels, S., Kim, Y. & Davis, F. G. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro. Oncol. 12, 520-527 (2010).
2. Louis, D. N. et al. (eds) WHO Classification of Tumours of the Central Nervous System (International Agency for research on Cancer, Lyon, 2007).
3. Wittwer, C. T. & Kusukawa, N. in Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (eds Burtis, C. A. et al.) 1407-1449 (Saunders, St Louis, 2006).
4. Bruns, D. E., Ashwood, e. r. & Burtis, C. A. (eds) Fundamentals of Molecular Diagnostics (Saunders, St Louis, 2007).
5. Farkas, D. H. & Holland, C. A. in Cell and Tissue Based Molecular Pathology (eds Tubbs, R. R. & Stoler, M. H.) 19-32 (Churchill Livingstone, Philadelphia, 2009).
6. Okamoto, Y. et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 108, 49-56 (2004).
7. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 11, 159-168 (2001).
8. Watanabe, T. et al. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J. Neuropathol. Exp. Neurol. 60, 1181-1189 (2001).
9. 6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol. 17, 5-10 (2007).
10. Fischer, U. et al. A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma. Mol. Cancer Res. 6, 576-584 (2008).
11. Dimitriadi, M. et al. p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours. Br. J. Cancer 99, 1144-1152 (2008).
12. Burger, P. C. What is an oligodendroglioma? Brain Pathol. 12, 257-259 (2002).
13. Smith, J. S. et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000).
14. Mueller, W. et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am. J. Pathol. 161, 313-319 (2002).
15. Barbashina, V., Salazar, P., Holland, E. C., Rosenblum, M. K. & Ladanyi, M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 11, 1119-1128 (2005).
16. Thon, N. et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J. Neuropathol. Exp. Neurol. 68, 1219-1228 (2009).
17. Jenkins, R. B. et al. A t (1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852-9861 (2006).
18. Griffin, C. A. et al. Identification of der (1;19) (q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol. 65, 988-994 (2006).
19. Fuller, C. E. & Perry, A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol. 12, 67-86 (2002).
20. Snuderl, M. et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin. Cancer Res. 15, 6430-6437 (2009).
21. Ichimura, K. et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 27, 2097-2108 (2008).
22. Jeuken, J., Cornelissen, S., Boots-Sprenger, S., Gijsen, S. & Wesseling, P. Multiplex ligationdependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J. Mol. Diagn. 8, 433-443 (2006).
23. 6-methylguanine-DNA methyltransferase activity on chloroethylnitrosourea chemotherapy in brain tumors. Int. J. Cancer 55, 76-81 (1993).
24. Preusser, M. et al. Anti-O6-methylguaninemethyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 18, 520-532 (2008).
25. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
26. 6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies. Oncol. Res. 7, 49-55 (1995).
27. 6-methylguanine-DNA methyltransferase expression in supratentorial diffuse low-grade astrocytoma. Surg. Neurol. 68, 603-608 (2007).
28. Everhard, S. et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann. Neurol. 60, 740-743 (2006).
29. Juillerat-Jeanneret, L. et al. Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest. 26, 597-609 (2008).
30. Lavon, I. et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin. Cancer Res. 13, 1429-1437 (2007).
31. Knobbe, C. B., Merlo, A. & Reifenberger, G. PTEN signaling in gliomas. Neuro. Oncol. 4, 196-211 (2002).
32. Fults, D. & Pedone, C. Immunocytochemical mapping of the phosphatase and tensin homolog (PTEN/MMAC1) tumor suppressor protein in human gliomas. Neuro. Oncol. 2, 71-79 (2000).
33. Ermoian, R. P. et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin. Cancer Res. 8, 1100-1106 (2002).
34. Zhou, X. P. et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer 84, 150-154 (1999).
35. Rasheed, A. et al. Molecular markers of prognosis in astrocytic tumors. Cancer 94, 2688-2697 (2002).
36. Walker, C. et al. Characterisation of molecular alterations in microdissected archival gliomas. Acta Neuropathol. 101, 321-333 (2001).
37. Broniscer, A. et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682-689 (2007).
38. Wiencke, J. K. et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro. Oncol. 9, 271-279 (2007).
39. Alvarez-Nunez, F. et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16, 17-23 (2006).
40. Goel, A. et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 64, 3014-3021 (2004).
41. Marsit, C. J. et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 36, 768-776 (2005).
42. Cecener, G. et al. Investigation of MMAC/PTEN gene mutations and protein expression in low grade gliomas. Cell. Mol. Neurobiol. 29, 733-738 (2009).
43. Dhomen, N. & Marais, R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 17, 31-39 (2007).
44. Bar, E. E., Lin, A., Tihan, T., Burger, P. C. & Eberhart, C. G. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J. Neuropathol. Exp. Neurol. 67, 878-887 (2008).
45. Pfister, S. et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J. Clin. Invest. 118, 1739-1749 (2008).
46. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
47. Korshunov, A. et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 118, 401-405 (2009).
48. Jones, D. T. et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28, 2119-2123 (2009).
49. Xu, X. et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279, 33946-33957 (2004).
50. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
51. Zhao, S. et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324, 261-265 (2009).
52. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
53. Aghili, M., Zahedi, F. & Rafiee, E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol. 91, 233-236 (2009).
54. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol. 118, 469-474 (2009).
55. Balss, J. et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116, 597-602 (2008).
56. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
57. Watanabe, T., Nobusawa, S., Kleihues, P. & Ohgaki, H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174, 1149-1153 (2009).
58. Ichimura, K. et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol. 11, 341-347 (2009).
59. Sanson, M. et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150-4154 (2009).
60. R132) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30, 7-11 (2009).
61. Kang, M. R. et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 125, 353-355 (2009).
62. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
63. Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339-344 (2010).
64. Paschka, P. et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J. Clin. Oncol. 28, 3636-3643 (2010).
65. Watanabe, T., Vital, A., Nobusawa, S., Kleihues, P. & Ohgaki, H. Selective acquisition of IDH1 r132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol. 117, 653-656 (2009).
66. Horbinski, C., Kofler, J., Kelly, L. M., Murdoch, G. H. & Nikiforova, M. N. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffinembedded glioma tissues. J. Neuropathol. Exp. Neurol. 68, 1319-1325 (2009).
67. Capper, D., Zentgraf, H., Balss, J., Hartmann, C. & Von Deimling, A. Monoclonal antibody specific for IDH1 r132H mutation. Acta Neuropathol. 118, 599-601 (2009).
68. Camelo-Piragua, S. et al. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol. 119, 509-511 (2010).
69. Pouratian, N., Asthagiri, A., Jagannathan, J., Shaffrey, M. E. & Schiff, D. Surgery Insight: the role of surgery in the management of lowgrade gliomas. Nat. Clin. Pract. Neurol. 3, 628-639 (2007).
70. Smith, J. S. et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J. Clin. Oncol. 26, 1338-1345 (2008).
71. Van Den Bent, M. J. et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366, 985-990 (2005).
72. Douw, L. et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 8, 810-818 (2009).
73. Shaw, E. G. et al. Final report of radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG) [abstract]. J. Clin. Oncol. 26, 2006 (2008).
74. Hashimoto, N. et al. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97, 2254-2261 (2003).
75. Fallon, K. B. et al. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol. 63, 314-322 (2004).
76. Mclendon, R. E. et al. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer 104, 1693-1699 (2005).
77. Kanner, A. A. et al. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J. Neurosurg. 104, 542-550 (2006).
78. Walker, C. et al. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann. Neurol. 57, 855-865 (2005).
79. Eoli, M. et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int. J. Cancer 119, 84-90 (2006).
80. Tosoni, A. et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J. Neurooncol. 89, 179-185 (2008).
81. Kesari, S. et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin. Cancer Res. 15, 330-337 (2009).
82. Jeon, Y. K. et al. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology 27, 10-20 (2007).
83. Weller, M. et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res. 13, 6933-6937 (2007).
84. Kuo, L. T. et al. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int. J. Cancer 124, 2872-2879 (2009).
85. Capelle, L. et al. Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J. Med. Imaging Radiat. Oncol. 53, 305-309 (2009).
86. Bauman, G. S. et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys. 48, 825-830 (2000).
87. Hoang-Xuan, K. et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J. Clin. Oncol. 22, 3133-3138 (2004).
88. 6- methylguanine DNA methyltransferase protein expression. Cancer 106, 1759-1765 (2006).
89. Buckner, J. C. et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21, 251-255 (2003).
90. Stege, E. M. et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 103, 802-809 (2005).
91. Pouratian, N. et al. Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. J. Neurooncol. 90, 341-350 (2008).
92. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 13, 176-184 (2003).
93. Van Den Bent, M. J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597-1604 (2010).
94. Labussiere, M. et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74, 1886-1890 (2010).
95. Dubbink, H. J. et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73, 1792-1795 (2009).
96. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).